At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 23 enrolled
Drug / intervention
IC51 has given in the parent study IC51-322 +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Long Term Immunity and Safety Following Vaccination With the Japanese Encephalitis Vaccine IC51(IXIARO®, JESPECT®) In a Pediatric Population in Non Endemic Countries. Uncontrolled, Phase 3 Follow-up Study
In Brief
A Phase 3 clinical trial evaluating Blood draw and IC51 has given in the parent study IC51-322 for Japanese Encephalitis. Completed, enrolled 23 participants across 5 sites in 3 countries.
Detailed Summary
The study investigates long-term immunity and safety of IC51 (IXIARO®, JESPECT®) in a pediatric population vaccinated in the parent study IC51-322.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsJapanese Encephalitis
CountriesAustralia, Germany, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2010
First PostedNov 2010
Primary CompletionOct 2012
Study CompletionSep 2014
TodayJul 2026
First PostedNov 23, 2010
Enrollment StartOct 1, 2010
Primary CompletionOct 1, 2012
Study CompletionSep 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 15.6 years ago
Interventions
Blood drawprocedure
blood draw at Month 12, Month 24 and Month 36.
IC51 has given in the parent study IC51-322biological
No more vaccinations in IC51-324 since this a study for long-term follow-up on safety and immunogenicity after vaccinations in parent study IC51-322.